Evidence map›Paper›PMID 29564386›Full record

ArticleEJNMMI radiopharmacy and chemistry2017

Optimizing labelling conditions of

Ho Sze Chan, Erik de Blois, Mark W Konijnenberg, Alfred Morgenstern, Frank Bruchertseifer, Jeffrey P Norenberg, Fred J Verzijlbergen, Marion de Jong, Wouter A P Breeman

Erratum issuedAbstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Facile transmetallation of [SbRSC advances · 2022
    Article
  3. Tuning the Kinetic Inertness of BiInorganic chemistry · 2021
    Article
  4. Erratum: Publisher Correction toEJNMMI radiopharmacy and chemistry · 2018
    Article
  5. Review
  6. Article
  7. Improved safety and efficacy ofEJNMMI research · 2016
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Ho Sze ChanErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Erik de BloisErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Mark W KonijnenbergErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Alfred MorgensternEuropean Commission, Joint Research Centre, Institute for Transuranium Elements (ITU), Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen, 76344 Karlsruhe, Germany.
Frank BruchertseiferEuropean Commission, Joint Research Centre, Institute for Transuranium Elements (ITU), Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen, 76344 Karlsruhe, Germany.
Jeffrey P NorenbergRadiopharmaceutical Sciences Program, College of Pharmacy, University of New Mexico Health Sciences Center, Albuquerque, 87131-0001 NM USA.
Fred J VerzijlbergenErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Marion de JongErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.
Wouter A P BreemanErasmus MC, Department of Radiology and Nuclear Medicine, 's-Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background

resultsAt least 3.5 nmol DOTATATE was required to obtain incorporation ≥ 99 % with 100 MBq

conclusion

Indexed as

213BismuthAbsorbed doseAscorbic acidRadiochemical puritySomatostatinTargeted alpha therapy

Identifiers

PMID29564386
PMCPMC5843812

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.